Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Regenxbio Inc
(NQ:
RGNX
)
12.13
+0.47 (+4.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
359,994
Open
11.72
Bid (Size)
11.48 (1)
Ask (Size)
12.81 (1)
Prev. Close
11.66
Today's Range
11.44 - 12.26
52wk Range
10.49 - 28.80
Shares Outstanding
43,466,186
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
7 Biotech Stocks to Buy for Their Game-Changing Potential
August 08, 2024
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.
Via
InvestorPlace
Where Regenxbio Stands With Analysts
August 05, 2024
Via
Benzinga
Performance
YTD
-33.86%
-33.86%
1 Month
-15.71%
-15.71%
3 Month
-18.92%
-18.92%
6 Month
-33.86%
-33.86%
1 Year
-33.17%
-33.17%
More News
Read More
Why Is Clearside Biomedical Stock Gaining Today?
June 25, 2024
Via
Benzinga
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
Via
InvestorPlace
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
June 21, 2024
Via
Benzinga
Exposures
Product Safety
Assessing Regenxbio: Insights From 4 Financial Analysts
June 07, 2024
Via
Benzinga
Evaluating Regenxbio: Insights From 9 Financial Analysts
May 15, 2024
Via
Benzinga
Where Regenxbio Stands With Analysts
April 12, 2024
Via
Benzinga
Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
March 06, 2024
Via
Benzinga
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
June 20, 2024
Via
Investor's Business Daily
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
June 13, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
Via
Benzinga
RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
March 25, 2024
Via
Benzinga
Regenxbio: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Via
Benzinga
A Preview Of Regenxbio's Earnings
February 26, 2024
Via
Benzinga
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
March 13, 2024
Via
The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
March 08, 2024
Via
Benzinga
REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
March 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 05, 2024
Via
Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 01, 2024
Via
Benzinga
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
February 12, 2024
Via
Benzinga
The One-Minute Market Report - Sunday, Feb. 11
February 11, 2024
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.